article thumbnail

Strategy Roundtable: Professional Investors Do Not Invest In $20 Million Markets

ReadWriteStart

These are areas that may be gaps in the portfolio of large companies, and are perfect for M&A deals in three to five years after building enough validation and $10-$20 million in revenue. Then Raymond McGlamery pitched the O-Port , a guitar and drum accessory company based in Houston, Texas. Ma Mi Skin Care.

article thumbnail

Strategy Roundtable: Professional Investors Do Not Invest In $20 Million Markets

www.readwriteweb.com

These are areas that may be gaps in the portfolio of large companies, and are perfect for M&A deals in three to five years after building enough validation and $10-$20 million in revenue. O-Port Then Raymond McGlamery pitched the O-Port , a guitar and drum accessory company based in Houston, Texas. This is her core market.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Strategy Roundtable: Professional Investors Do Not Invest In $20 Million Markets

www.readwriteweb.com

These are areas that may be gaps in the portfolio of large companies, and are perfect for M&A deals in three to five years after building enough validation and $10-$20 million in revenue. O-Port Then Raymond McGlamery pitched the O-Port , a guitar and drum accessory company based in Houston, Texas. This is her core market.

article thumbnail

Episode 14: Be Your Own Boss, Restaurant Owners, and Friendliest Cities for Businesses | The Bcast

Up and Running

It seems like there’s so much variety, and if anything it seems like there’s increasing innovation and sort of differentiation amongst these businesses. We’ve got another Texas city, Houston, number seven. Whether it’s a restaurant, a food cart, distributor, it’s a wild space. Jonathan: Yeah.

Texas 60
article thumbnail

The Ezra Klein Show: VC Bill Gurley on Transforming Health Care

abovethecrowd.com

market in terms of revenue dollars (there is no question that digital tools will successfully impact specific acute diseases/disorders, but it’s our intuition these are best left to 100% focused HC investors). People price differentiate all the time. Isn’t Stanford just giving you better MRIs?